Lacosamide given by vein for sudden trigeminal neuralgia pain in emergency care
Looks at lacosamide for sudden trigeminal neuralgia pain in adults seen in emergency departments.
Key facts
- Who runs it
- Hospital Universitari de Bellvitge
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 21 Apr 2025
- Expected to end
- Dec 2027
- Type of study
- Observational
- Treatments tested
- Lacosamide
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with trigeminal neuralgia who come to the emergency department of Hospital de Bellvitge with a sudden worsening of pain. Their doctor must have prescribed intravenous lacosamide for the pain.
- Age
- Over 18 years.
- Sex
- All sexes can join.
- Disease stage
- Classical or idiopathic trigeminal neuralgia, diagnosed by the ICHD-3 criteria, with an acute pain flare.
- Earlier treatment
- The treating doctor must have prescribed intravenous lacosamide for the pain flare.
Main reasons for not taking part
- People who cannot take lacosamide, such as after a past allergic reaction to it
- People with a known atrioventricular block (a heart rhythm problem)
- A mental or psychiatric illness that makes it hard to understand and sign the consent form
- A language barrier
- Lack of cooperation
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3)
- Age over 18 years
- Signed informed consent
Who cannot take part
- Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block)
- Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent
- Language barrier
- Lack of cooperation
Other criteria
- All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion
This trial is currently available in Spain.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective observational study evaluates the effectiveness and safety of intravenous lacosamide as a rescue treatment for acute pain in patients presenting to the emergency department with trigeminal neuralgia
Treatments tested
- Lacosamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia: A Prospective Observational Study
- Plain-language title
- Lacosamide given by vein for sudden trigeminal neuralgia pain in emergency careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 15 September 2026